Clinical Trials Arena

DT120 has now posted positive results in both GAD and MDD, setting the stage for its potential foray into the neuropsychiatric market.The post Definium's psychedelic prospects brighten further on Phase III success appeared first on Clinical Trials Arena.

Belenos and Keymed will now look to initiate Phase III studies for their co-developed drug in Dupixent-dominated CRSwNP.The post Belenos' Keymed licensing deal delivers on Phase II win in rhinosinusitis appeared first on Clinical Trials Arena.

The manufacturing floor represents the primary source of life sciences compliance risks and data integrity failures.The post Why your manufacturing floor is your greatest compliance risk - and opportunity appeared first on Clinical Trials Arena.

The CRISPR therapy, SNIPR001, was administered to the patient who had developed E. Coli following a single-patient emergency IND.The post Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli appeared first on Clinical Trials Aren

Arch Biopartners is set to expand its Phase II clinical trial of LSALT peptide, a drug candidate targeting CS-AKI, to clinical sites in the US.The post Arch Biopartners plans US expansion of LSALT peptide trial appeared first on Clinical Trials Arena.

Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene therapy for children with hearing loss linked to GJB2 gene changes.The post First patient in Skylark Bio's Phase I/II trial receives SKY-

The PsA data follows a successful readout for MoonLake's drug in HS earlier in 2026.The post MoonLake's nanobody boosts PsA indication hopes after Phase III success appeared first on Clinical Trials Arena.

Launching a product across Europe's fragmented healthcare systems presents unique challenges that first-timers are often unprepared for, say experts from Cencora.The post Commercialising drugs in Europe: Lean models for first-time launchers appeared first

If Silence's divesiran reaches the PV market, it could become the first siRNA therapy in an indication dominated by Jakafi and Besremi.The post Silence's stock soars on divesiran's Phase II polycythaemia vera success appeared first on Clinical Trials Aren

Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.The post Tenax Therapeutics' stock crashes on Phase III trial failure appeared first on Clinical Trials Arena.